TeraWulf Stock Gets Major Boost from Analyst Upgrade
Keefe Bruyette upgrades TeraWulf to Outperform, raising its price target to $24 and highlighting strong growth potential from its business shift.
NOTRELOAD AI
FDA Fast-Tracks Review of New Alzheimer's Agitation Treatment
Axsome's AXS-05 gets FDA priority review for treating agitation in Alzheimer's patients, with decision expected by April 2026.
ByteDance Plans $14 Billion Nvidia Chip Investment for 2026
ByteDance to increase AI chip spending to 100 billion yuan ($14 billion) in 2026, up from $85 billion yuan in 2025, while developing its own processors to reduce costs.
Vanda Pharmaceuticals Stock Soars on FDA Approval of Motion Sickness Drug
Vanda Pharmaceuticals shares jump 19% in premarket trading after FDA approves Nereus, the first new motion sickness treatment in 40 years.
Nike CEO Elliott Hill Buys $1 Million in Company Stock as Insider Confidence Grows
Nike CEO Elliott Hill purchased $1 million worth of NKE shares at $61.10, while Chairman Emeritus Phil Knight acquired 4.5 million convertible shares, signaling insider confidence.
Flushing Financial Stock Drops 9% on OceanFirst Merger News
Flushing Financial shares tumbled nearly 9% after announcing its acquisition by OceanFirst Financial in a $579 million deal backed by Warburg Pincus investment.